乌司他丁在自身免疫性肝病合并慢加急性肝衰竭治疗中的作用

Role of Ulinastatin in treatment of acute-on-chronic liver failure combined with autoimmune liver diseases

目的探讨乌司他丁治疗自身免疫性肝病合并慢加急性肝衰竭的效果。方法选取2011年1月-2012年12月诊断的自身免疫性肝病合并慢加急性肝衰竭患者20例,分为治疗组和对照组,治疗组在常规治疗的基础上加用乌司他丁,其余治疗措施两组相同。结果经过7 d的治疗,治疗组患者的AST水平低于对照组(P=0.03),IL-6下降的水平较对照组明显(P<0.05);两组在ALT水平(P=0.61)和MELD评分(P=0.36)方面的差异无统计学意义。结论乌司他丁治疗自身免疫性肝病合并慢加急性肝衰竭具有积极作用,尤其在降低炎性因子方面效果明显。

Objective To evaluate the efficacy of Ulinastatin in treatment of acute-on-chronic liver failure combined with autoimmune liver diseases. Methods 20 patients diagnosed as acute-on-chronic liver failure combined with autoim- mune liver diseases in the PLA General from Jan. 2011 to Dec. 2012 were divided into treatment group and control group. On the basis of routine therapy, treatment group was administered with Ulinastatin and other interventions were similar between two groups. Results After 7-day treatment, the level of serum ALT was lower in the treatment group than that in the control group （P = 0.03） , and IL-6 was decreased more significantly in the treatment group than that in the control group （P 〈 0.05 ）. However, no statistical significance existed between two groups in serum ALT level （ P = 0.61 ） and MELD scores （P = 0.36）. Conclusion Ulinastatin is positive in treatment of acute-on-chronic liver failure combined with autoimmune liver diseases, especially in decreasing the levels of inflammatory factors.